Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Condition: Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Grade III Meningioma; Adult Meningeal Hemangiopericytoma; Adult Meningioma; Recurrent Adult Brain Tumor
MeSH terms: Meningioma; Hemangiopericytoma; Solitary Fibrous Tumors; Recurrence
Intervention: imatinib mesylate; laboratory biomarker analysis; pharmacological study
Intervention description: Given orally; Correlative studies; Correlative studies
Intervention MeSH terms: Imatinib Mesylate
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 23.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
      recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the
      enzymes necessary for tumor cell growth
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed meningioma

               -  Benign, malignant, or atypical disease

               -  Neurofibromatosis (NF) type 1 or 2 allowed

               -  Hemangiopericytoma allowed

          -  Unequivocal evidence of tumor recurrence or progression by MRI or CT scan (on steroid
             dosage that is stable for at least 5 days)

          -  Evaluable residual disease by MRI or CT scan if previously treated with surgical
             resection for recurrent or progressive disease

          -  Newly diagnosed recurrent disease that requires surgical debulking allowed

          -  Prior standard external-beam radiotherapy, interstitial brachytherapy, or gamma-knife
             radiosurgery allowed provided disease has progressed since completion of therapy

               -  Patients who have had prior brachytherapy or stereotactic radiosurgery must have
                  confirmation of true progressive disease rather than radiation necrosis based
                  upon positron-emission tomography or thallium scanning, magnetic resonance
                  spectroscopy, or surgical documentation

          -  Patients with a history of NF may have other stable Central Nervous System (CNS)
             tumors (e.g., schwannoma, acoustic neuroma, or ependymoma) provided those lesions have
             been stable in size for the past 6 months

          -  Performance status - Karnofsky 60-100%

          -  More than 8 weeks

          -  Absolute neutrophil count at least 2,000/mm^3

          -  Platelet count at least 120,000/mm^3

          -  Hemoglobin at least 10 g/dL (transfusions allowed)

          -  No bleeding disorders

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) less than 2 times ULN

          -  Prothrombin Time (PT), Partial thromboplastin time (PTT), and International normalized
             Ratio (INR) no greater than 1.5 times ULN

          -  Creatinine less than 1.5 mg/dL

          -  Creatinine clearance at least 60 mL/min

          -  No deep venous or arterial thrombosis within the past 6 weeks

          -  No pulmonary embolism within the past 6 weeks

          -  No serious active infection

          -  No prior intracranial hemorrhage

          -  No concurrent disease that would obscure toxicity or dangerously alter drug metabolism

          -  No other malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
             unless the patient is in complete remission and off all therapy for that disease for
             at least 3 years

          -  No other significant medical illness that would preclude study participation

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after study participation

          -  At least 1 week since prior interferon or thalidomide

          -  No concurrent immunotherapy

          -  Concurrent epoetin alfa allowed

          -  At least 4 weeks since prior cytotoxic chemotherapy

          -  At least 2 weeks since prior vincristine

          -  At least 6 weeks since prior nitrosoureas

          -  At least 3 weeks since prior hydroxyurea or procarbazine

          -  No concurrent chemotherapy

          -  At least 1 week since prior tamoxifen

          -  No concurrent hormonal therapy

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

          -  Recovered from prior surgery

          -  Recovered from all prior therapy

          -  At least 1 week since prior noncytotoxic therapy (e.g., isotretinoin) except
             radiosensitizers

          -  At least 2 weeks since prior drugs that affect hepatic metabolism

          -  At least 4 weeks since prior investigational agents

          -  No concurrent warfarin (heparin or low-molecular weight heparin allowed)

          -  No other concurrent investigational agents

          -  No concurrent acetaminophen of more than 500 mg/day

          -  No other concurrent anticancer therapy